Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Dow
Johnson and Johnson
Baxter
Moodys

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,273,894


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,273,894 protect, and when does it expire?

Patent 8,273,894 protects YUPELRI and is included in one NDA.

This patent has thirty-eight patent family members in twenty-seven countries.

Summary for Patent: 8,273,894
Title:Biphenyl compounds useful as muscarinic receptor antagonists
Abstract: This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s): Mammen; Mathai (Menlo Park, CA), Ji; YuHua (Redwood City, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:13/438,105
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,273,894

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Ireland Ltd YUPELRI revefenacin SOLUTION;INHALATION 210598-001 Nov 9, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,273,894

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048032 ⤷  Try it Free
Argentina 104444 ⤷  Try it Free
Austria 395335 ⤷  Try it Free
Austria 467617 ⤷  Try it Free
Australia 2005222411 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Moodys
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.